1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Simcere Pharmaceutical Group Limited
  6. News
  7. Summary
    2096   HK0000658531

SIMCERE PHARMACEUTICAL GROUP LIMITED

(2096)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Certain Ordinary Shares of Simcere Pharmaceutical Group Limited are subject to a Lock-Up Agreement Ending on 26-OCT-2021.

10/26/2021 EDT

Certain Ordinary Shares of Simcere Pharmaceutical Group Limited are subject to a Lock-Up Agreement Ending on 26-OCT-2021. These Ordinary Shares will be under lockup for 368 days starting from 23-OCT-2020 to 26-OCT-2021. Details: The controlling shareholders have agreed not to dispose off any shares for 6 months from the listing date. The controlling shareholders will also not dispose off any shares for further 6 months, if such disposal leads to the shareholder ceasing to be a controlling shareholder.


© S&P Capital IQ 2021
All news about SIMCERE PHARMACEUTICAL GROUP LIMITED
05/17Simcere Pharma Cleared to Start Clinical Study of COVID Drug in China; Shares Slide 4%
MT
05/16Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0417 Issu..
CI
04/18Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in Clinical Trials, Market App..
PR
04/06SIMCERE PHARMA (HK.2096) to host 2022 R&D Day
PR
04/01Simcere Pharma Wins Nod to Start Clinical Trial in China of COVID Treatment
MT
03/31Simcere Pharmaceutical Group Limited Obtains Permission from the National Medical Produ..
CI
03/30UBS Adjusts Simcere Pharmaceutical's Price Target to HK$12.50 From HK$11.80, Keeps at B..
MT
03/25Simcere Pharma's Earnings Climb in 2021 on Higher Revenue From Innovative Pharmaceutica..
MT
03/24Simcere Pharmaceutical Group Limited Proposes Final Ordinary Dividend for the Year Ende..
CI
03/24Simcere Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended D..
CI
More news
Analyst Recommendations on SIMCERE PHARMACEUTICAL GROUP LIMITED
More recommendations
Financials (USD)
Sales 2022 991 M - -
Net income 2022 159 M - -
Net Debt 2022 411 M - -
P/E ratio 2022 23,1x
Yield 2022 0,68%
Capitalization 3 307 M 3 307 M -
EV / Sales 2022 3,75x
EV / Sales 2023 3,14x
Nbr of Employees 6 182
Free-Float 19,7%
Chart SIMCERE PHARMACEUTICAL GROUP LIMITED
Duration : Period :
Simcere Pharmaceutical Group Limited Technical Analysis Chart | 2096 | HK0000658531 | MarketScreener
Technical analysis trends SIMCERE PHARMACEUTICAL GROUP LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 8,38 CNY
Average target price 10,78 CNY
Spread / Average Target 28,6%
EPS Revisions
Managers and Directors
Jin Sheng Ren President
Yu Shan Wan Chief Financial Officer & Executive Director
Pin Wang Chief Scientific Officer
Rui Lin Song Independent Non-Executive Directors
Jian Guo Wang Independent Non-Executive Director